glycine has been researched along with Refractory Anemia in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly patients with relapsed or refractory acute myeloid leukaemia (AML)." | 2.78 | Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. ( Advani, AS; Charman, A; Cortes, J; Feldman, E; Kantarjian, H; Rizzieri, D; Spruyt, R; Toal, M; Yee, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, H | 1 |
| Huang, Z | 1 |
| He, L | 1 |
| Yuan, F | 1 |
| Sun, L | 1 |
| Liu, F | 1 |
| Xiao, L | 1 |
| Aschenbrenner, DS | 1 |
| Cortes, J | 1 |
| Feldman, E | 1 |
| Yee, K | 1 |
| Rizzieri, D | 1 |
| Advani, AS | 1 |
| Charman, A | 1 |
| Spruyt, R | 1 |
| Toal, M | 1 |
| Kantarjian, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia[NCT00780598] | Phase 2 | 76 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for glycine and Refractory Anemia
| Article | Year |
|---|---|
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Cytarabine; Disease-Free Survival; Female; Glycine; Hum | 2013 |
2 other studies available for glycine and Refractory Anemia
| Article | Year |
|---|---|
Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor.
Topics: Anemia, Refractory; Autoantibodies; Bone Marrow; Erythropoietin; Female; Glycine; Humans; Hypoxia-In | 2020 |
First Drug Approved for Patients with Refractory AML and Mutation in the IDH1 Gene.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Antineoplastic Agents; Female; Glycine; Humans; | 2018 |